2020.05.20
I-Mab expands its global presence! The new office in Hong Kong is officially open as the regional hub for capital markets and investor relations activities for I-Mab. This newest addition will bring our team of best talents from around the world even closer to investors, capital markets practitioner...
2020.05.13
I-Mab announced that the first patient has been dosed in a Phase 1/2 clinical study in China to evaluate I-Mab's proprietary CD73 antibody TJD5 in patients with advanced solid tumors. TJD5 is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that...
2020.04.29
I-Mab today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2019 with the U.S. Securities and Exchange Commission on April 29, 2020.
2020.04.28
I-Mab and MorphoSys AG today jointly announced that the first patient has been dosed in a phase 3 clinical study in mainland China to evaluate MorphoSys' investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide plus dexamethasone in patients with relapsed or refractory multi...
2020.04.24
Distinguished clinical experts from the US and China gathered on 18 April, via virtual webinar, to share insights and important lessons from the frontlines of treating and managing COVID-19 patients.
2020.04.24
I-Mab today announced its participation in the following conferences in May. Details of the conferences and management presentation are as follows: - Bank of America Securities Global Virtual Healthcare Conference - Citi Virtual Pan-Asia Regional Investor Conference.
2020.04.03
I-Mab announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate clinical study for TJM2 to treat cytokine release syndrome (CRS) associated with severe illness caused by the coronavirus disease 2019 (COVID-19).
2020.04.02
- The clinical study will evaluate the safety and preliminary efficacy of TJC4, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - Initiation of development of TJC4 in China follows an ongoing Phase 1 study in U.S. for advanced solid tumors and ...
2020.03.31
- Successfully completed initial public offering raising approximately $114.5 million in gross proceeds - Continued execution across broad pipeline portfolio; multiple clinical data readouts expected in 2020 - Company to host conference call and webcast, March 31 at 8:00 a.m. EDT
2020.03.30
- Kalbe Genexine Biologics (“KG Bio”) will receive right of first negotiation for an exclusive license to potentially commercialize I-Mab’s TJD5, in Southeast Asia and other territories - Partnership to include right of first negotiation on an additional I-Mab-discovered product candidate to be agr...